The committee noted that semaglutide tablets 3 mg, 7 mg, and 14 mg are approved for marketing in India. The firm has claimed ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Although research suggests that flavonoids may promote insulin secretion by inhibiting glucagon secretion in T2DM, thereby preserving GIP levels, these observations have not been confirmed by ...

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, and growing consumer demand ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

A study from the Arkansas Agricultural Experiment Station finds that GLP-1 medications, such as Ozempic and Wegovy, are ...

Five researchers have been jointly awarded one of this year's Breakthrough Prizes in Life Sciences for their contributions to the development of Ozempic-style drugs.

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...